003520.KS
Yungjin Pharm. Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 931.00
−2.10%Year over year
Reported trailing growth
- Revenue
- +0.6%
- EBITDA
- -85.9%
- EBIT
- —
- EPS
- —
- Free cash flow
- -14.4%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- +26.3%
- EBIT
- +4.7%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026